Risk and outcomes of COVID-19 in patients with multiple sclerosis
European Journal of Neurology — Moreno-Torres I, Lallana VM, Costa-Frossard L, et al. | June 23, 2021
In this observational study, researchers sought to examine the risks of SARS-CoV-2 infection and COVID-19–related outcomes in patients with multiple sclerosis (MS), and compare these with the general population. A regional registry was established to collect data on the incidence, hospitalization rates, intensive care unit admission, and death in MS and COVID-19 patients. Between February and May 2020, 14 specialist MS treatment centers in Madrid, Spain, participated in the study. The registry included 219 patients, 51 of whom were hospitalized with COVID-19. Males with MS had a higher incidence rate and were more likely to be hospitalized than females. There was no link discovered between the use of any disease-modifying treatment and the risk of hospitalization. When compared with the general population, patients with MS do not seem to be at a higher risk of SARS-CoV-2 infection or severe COVID-19 outcomes. A careful risk-benefit analysis should be used to decide whether to begin or continue disease-modifying treatment.